Ignite Creation Date:
2024-05-05 @ 4:52 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00330915
Status:
COMPLETED
Last Update Posted:
2009-07-21
First Post:
2006-05-26
Brief Title:
A Study of Pemetrexed and Folic Acid Given Before Surgery Neoadjuvant Treatment to Patients With Rectal Cancer
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Feasibility Study of Pemetrexed Single Agent and Folic Acid Given as Neoadjuvant Treatment in Patients With Resectable Rectal Cancer
Status:
COMPLETED
Status Verified Date:
2009-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to help answer the following research questions
If the study drug Pemetrexed can help patients with rectal cancer If molecular biological parameters are correlated respectively changing due to cytotoxic treatment with Pemetrexed To evaluate adverse events
If the study drug Pemetrexed can help patients with rectal cancer If molecular biological parameters are correlated respectively changing due to cytotoxic treatment with Pemetrexed To evaluate adverse events
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H3E-MC-S077 | None | None | None |